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minimum of 10 d. Patients should be 
retested for ongoing viral secretion ev-
ery 5 d and negative results confi rmed 
with a follow-up sample after 48 h. 
Classic virus isolation in addition to 
molecular methods may also identify 
potentially infectious patients.
Prophylactic neuraminidase in-
hibitor use in such patients also needs 
to be addressed. Resistance is more 
likely with the reduced prophylactic 
dose of oseltamivir and is more likely 
to be a problem in immunocompro-
mised patients. Zanamivir is now the 
drug of choice for prophylaxis for 
such patients, although some experts 
propose no prophylaxis and instead 
early treatment after symptom onset 
(9).
Immunocompromised patients 
are more likely to shed virus for pro-
longed periods and are more likely to 
develop oseltamivir-resistance, espe-
cially when this drug is used as mono-
therapy. Further clinical experience 
and trials will support or refute newer 
guidelines on the management of pan-
demic (H1N1) 2009 in such patients.
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To the Editor: Contrary to no-
rovirus (NoV) infections, sapovirus 
(SaV) is believed to affect mainly 
young children (1), although recent 
studies show that SaV is present in all 
age groups (2,3). SaV has been clas-
sifi ed into 5 genogroups, of which 
GI, GII, GIV, and GV affect humans 
(4). SaV can be transmitted in vari-
ous ways, including person-to-person 
fecal–oral route, by aerosol, and by 
consumption of contaminated food or 
water (5). Outbreaks of SaV have been 
reported in various settings but are less 
common than NoV outbreaks (1,6).
During October 2–7, 2008, an 
outbreak of gastroenteritis occurred 
in a rehabilitation center in Upper 
Austria. Signs including diarrhea, 
vomiting, and fever developed in 21 
adult patients and 12 staff members. 
The observed signs and the likely 
incubation period initially suggested 
NoV as the cause of the outbreak. 
Stool specimens of 10 patients were 
collected and submitted to the Insti-
tute for Medical Microbiology and 
Hygiene in Graz.
Along with microbiologic inves-
tigations, infection control measures 
were introduced by local authorities 
on each affected ward. The earliest re-
ported onset of illness was on October 
2, 2008, in a 52-year-old woman on the 
third fl oor. The next day 2 additional 
patients on the same fl oor and 1 mem-
ber of the kitchen staff showed symp-
toms. Another 7 patients, on 3 differ-
ent fl oors, and 2 of the medical staff 
suffered from symptoms the following 
day (October 4). The outbreak peaked 
with 11 cases 3 days after the initial 
episode of vomiting. An additional 9 
persons became infected (5 patients, 
a doctor, janitor, psychotherapist, and 
kitchen worker) within the following 
2 days. The affected patients were pre-
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dominantly elderly; mean age was 54 
years (range 20–81 years, male:female 
ratio 1:0.83). Clinical signs continued 
for 24 hours.
Routine microbiologic cultures for 
enteric bacterial pathogens were per-
formed and showed negative results. A 
NoV-specifi c 1-tube real-time PCR as-
say (LightCycler 2.0; Roche Applied 
Science, Mannheim, Germany) with 
primers/probes reported by Hoehne 
et al. (7) and ELISAs (Ridascreen; R-
Biopharm AG, Darmstadt, Germany) 
were conducted to detect rotavirus and 
adenovirus antigen. All tests yielded 
negative results. Subsequently, 5 of 
10 samples were submitted to the 
Robert Koch Institute in Berlin for 
further investigation. SaV was identi-
fi ed in 4 samples by using the reverse 
transcription–PCR described by Oka 
et al. (8); mean viral load was 2.65 × 
108 RNA copies/g stool (range 3.3 × 
107–7.7 × 108 copies/g stool). Direct 
sequencing of the appropriate amplifi -
cation product showed 100% identical 
nucleotide sequences, which indicated 
1 causative strain.
Retrospective testing of the 10 
specimens showed 9 SaV-positive 
samples. Subsequently, genotyping 
was conducted by using a 1,130-bp 
amplifi cation product of the poly-
protein gene open reading frame 1 
spanning the recombination site at 
the junction between the polymerase 
gene and the capsid gene. One speci-
men was amplifi ed by RT-nested 
PCR with sense primer SV 53a (5′-
TAGACTACAGCAAGTGGGA-3′, 
nt position 4356–4374), antisense 
primer SV 63 (5′-ACACCATGT
TGGACACGCTGC-3′, nt position 
6901–6881), and SuperScript III One-
Step RT-PCR System with Platinum 
Taq High Fidelity (Invitrogen, Paisley, 
UK) for the fi rst-round PCR. For the 
second-round PCR, the HotStarTaq 
Master Mix Kit (QIAGEN, Hilden, 
Germany) and primer SV 55a (5′-
CCMTCKGGCATGCCATTCAC-3′, 
nt position 4529–4548) and SV60 (5′-
ATGTTAAATGTGATAGGATCCA
C-3′, nt position 5658–5636) were 
used (nucleotide positions according to 
GenBank accession no. DQ058829).
Phylogenetic analysis of the sec-
ond-round PCR product (GenBank ac-
cession no. GU724600) showed 97% 
nucleotide identity to the strain An-
gelholm/SW278/2004/SE (GenBank 
accession no. DQ125333), which is 
a known intergenogroup recombinant 
virus (II.2/ IV) as seen in Japan and 
Sweden (9). Thus, by sequence analy-
sis of the polymerase region, our strain 
Graz1561/2008/Austria was grouped 
into genogroup II; the capsid region 
belonged to genogroup IV.
Diarrhea and vomiting were the 
most common signs in patients, 97% 
and 73%, respectively. Fever was re-
corded for only 1 case-patient. Our 
fi ndings are consistent with those of 
SaV outbreak studies in adults reported 
by Johansson et al. (3), who reported 
diarrhea in 72% and vomiting in 56% 
of the case-patients they studied.
The new genetic background of 
the recombinant virus may have en-
hanced host susceptibility by evading 
the immune response and is therefore 
able to affect adults. Our study shows 
that SaV causes outbreaks of gastroen-
teritis in adults; consequently, the role 
of SaV in the adult population should 
be reconsidered. We suggest that diag-
nostics for SaV should be included in 
the study of gastroenteritis outbreaks 
in adults, especially when clinical 
signs suggest NoV as the causative 
agent but no diagnostic confi rmation 
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